A promising antigen, interleukin-13 receptor alpha 2 (IL13Rα2), is overexpressed in melanoma and linked to tumor invasiveness and poor prognosis; IL13Rα2-targeted CAR T-cells are currently being studied in a Phase I clinical trial (NCT04119024). This evidence concerns the gene IL13RA2 and neoplasm.